Solvay Pharmaceuticals, Gmbh

Kali-chemie Pharma Gmbh

Abbott Healthcare Products B.v.

Abbott Products Gmbh

Dieter Ziegler

Reinhard Brueckner

Michael Weske

Yvan Fischer

Michael Mlinaric

Yasmin Karimi-Nejad

Josef Messinger

Klaus Witte

Lechoslaw Turski

Uwe Schoen

Wolfgang Kehrbach

Dagmar Hoeltje

Axel Pahl

Hrissanthi Ikonomidou

Brian Moloney

Katrin Michaelis

Constanze Hoefer

Christiane Boecker

Lester Marrison

Elbert Kaan

Jochen Antel

Gerhard-Wilhelm Bielenberg

Arman Farjam

David Sykes

Willi Bielenberg

Willy Deleersnijder

Samuel David

Gerd Buschmann

Christian Eeckhout

Ulrich G Kuhl

Uwe Schon

Bernd Eisele

Matthias Straub

Paulus Antonius Remigius Koopman

Michael Peck

Jan H Van Maarseveen

Jack A Den Hartog

Chris G Kruse

Jan-Hendrik Reinders

Heinz Rupp

Bodo Jaeger

Bernhard Maisch

Chen Bing

Gareth Williams

Polypeptides which are related to the neprilysin enzyme family and have zinc metalloprotease activities and are referred to as IGS5, polynucleotides encoding such polypeptides, vectors containing such polynucleotides, host cells containing such vectors, processes for producing such polypeptides and/or polynucleotides, screening methods for identifying compounds which stimulate or inhibit IGS5 polypeptides and/or polynucleotides, and the use of such polypeptides and/or polynucleotides in therapy of various dysfunctions, disorders or diseases, particularly cardiovascular diseases, metabolic diseases such as diabetes mellitus type II, and neurodegenerative disorders, such as Parkinson's Disease.

Screening and treatment methods using IGS5 enzymes of the metalloprotease family

Compounds corresponding to formula I, wherein R, R, R, R, R, R, R, R, R, Rand n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.

[object Object]

A combination therapy is disclosed for treating or inhibiting cardiovascular or metabolic diseases or conditions through a combination of at least one inhibitor of neutral endopeptidase (=NEP), at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor. Pharmaceutical compositions are also described comprising NEP inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors and the use of these pharmaceutical composition in the prophylaxis or treatment of cardiovascular and/or metabolic disorders or diseases in mammals (including humans).

Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors

The use of compounds corresponding to formula I: in which R, R, R, R, Rand Rhave the meanings given in the description for treating cardiac arrhythmias and other disease states.

Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R, R, Rand Rhave the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them

Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them

Compounds corresponding to formula I: in which R, R, R, R, Rand Rhave the meanings given in the description; a process for the preparation of these compounds; intermediate products used to prepare such compounds, and pharmaceutical compositions containing such compounds.

Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them

The use of selective imidazoline receptor agonists, such as moxonidine, rilmenidine, LNP-509, S-23515, PMS-812, PMS-847 and BU-98008, and their physiologically compatible acid addition salts in pharmaceutical preparations for the treatment and/or inhibition of functional disorders and/or diseases in larger mammals or humans which require inhibition or reduction of the activity of proteins which regulate the intracellular pH value and which belong to the superfamily of bicarbonate transporters, in particular the treatment or inhibition of clinical conditions of bones which are caused by an undesirable amount of bone resorption, such as osteoporosis; of diseases of the gastrointestinal tract, such as gastric ulcers; and of neuronal and/or neuropsychiatric diseases associated with a pathologically altered (especially increased) neuronal activity, such as depression, Alzheimer's disease, eating disorders and schizophrenia.

Method for the treatment of diseases requiring inhibition or a reduction in the activity of pH value-regulating bicarbonate transporter proteins

Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R, R, Rand Rhave the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

3-phenyl-3,7-diazabicyclo&lsqb;3.3.1&rsqb; nonane compounds, process for preparing them, pharmaceutical compositions containing them and use thereof to inhibit cardiac arrhythmia

The use of moxonidine an its physiologically compatible acid-addition salts for the treatment and/or prophylaxis of disorders of thermogenesis and for the stimulation of thermogenesis in persons with abnormally reduced energy turnover and/or persons with reduced thermogenesis during or following a weight loss diet is disclosed.

Thermogenesis stimulating drugs

Neurokinin-antagonistic compounds corresponding to formula I: ##STR1## in which R.sup.1 is hydrogen or lower alkyl,

7-phenyl-1, 4-diazepane compounds, process for their preparation, and

Growing community of inventors

Hemmingen, Germany

Dieter Ziegler